Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Liu et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d7d52f2f3446b9d5d17ec5 — DOI: https://doi.org/10.1200/jco.20.01055

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer· 2018 · 3,453 citations
2. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer· 2015 · 47 citations
3. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial· 2016 · 1,252 citations
4. Fine‐needle aspiration and core needle biopsy: An update on 2 common minimally invasive tissue sampling modalities· 2016 · 109 citations
5. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab· 2018 · 1,191 citations